98%
921
2 minutes
20
Background: Characterizing clustering rates of people with HIV in high-risk populations can offer insights on the HIV epidemic, enhancing efforts to control its spread.
Methods: We investigated longitudinal dynamics of clustering rates among individuals newly diagnosed with HIV-1. Data were extracted from medical records of all people with HIV in Rhode Island with available viral sequences. Partial pol sequences were grouped by HIV diagnosis year, and clusters were identified in annual phylogenies. Clustering trends were estimated within eleven socio-demographic variables using the Mann-Kendall statistic. Associations with clustering propensity and changes over time were tested using generalized linear mixed-effects models.
Results: HIV-1 sequences from 2,630 individuals representing the statewide epidemic were analyzed across 33 annual datasets (1991-2023). Over this period, a continuous increase in clustering rates among newly diagnosed individuals was observed despite decreasing diagnoses over the last decade. Significant clustering upward trends were seen among newly diagnosed men who have sex with men, males, the 21-40 age group, non-Hispanic or Latino individuals, Whites, individuals with subtype B, and USA-born individuals, but not among individuals who inject drugs, females, and incarcerated individuals. Analyses of relative associations between groups within variables further corroborated these results.
Conclusions: Analyses focusing on molecular HIV clusters among newly diagnosed individuals in a statewide epidemic over three decades revealed significant evolving trends among those at highest risk of HIV transmission, patterns not seen in the overall population. These findings inform the design and development of targeted public health interventions aimed at high-risk populations to curb HIV spread.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/infdis/jiaf313 | DOI Listing |
Anticancer Drugs
September 2025
Department of Blood and Marrow Transplantation, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer.
Bortezomib resistance in multiple myeloma (MM) is a significant clinical challenge that limits the long-term effectiveness. Currently, there is a lack of reliable biomarkers to predict bortezomib resistance. Previous studies reported that several proteins regulate bortezomib resistance through targeting ubiquitin-proteasome pathways, including heat shock protein family A member 9 (HSPA9), dickkopf Wnt signaling pathway inhibitor 1 (DKK1), proteasome 26S subunit non-ATPase 14 (PSMD14), and tripartite motif containing 21 (TRIM21).
View Article and Find Full Text PDFNeurodegener Dis Manag
September 2025
RWE Statistics, KMK Consulting, Inc, North Tower, Morristown, NJ, USA.
Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with diverse symptoms that complicate diagnosis. We aimed to characterize MSA-related symptoms, medications, and healthcare resource utilization (HCRU).
Research Design And Methods: This retrospective cohort study used a large US claims database.
Cardiovasc Hematol Agents Med Chem
September 2025
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Background: Pulmonary Hypertension (PH) is a significant contributor to cardiac mortality in Dilated Cardiomyopathy (DCM) patients. Inflammatory processes and oxidative stress play pivotal roles in the advancement of Pulmonary Hypertension (PH). The Monocyte-to-High-- Density-Lipoprotein Cholesterol Ratio (MHR), a newly identified biomarker indicative of inflammatory and oxidative stress, has not been extensively researched in the context of pulmonary hypertension, especially within the scope of dilated cardiomyopathy.
View Article and Find Full Text PDFAnal Chim Acta
November 2025
Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266071, China. Electronic address:
Background: Lung ischemia-reperfusion injury (LIRI) is a pathological condition characterized by aggravated oxidative-inflammatory tissue damage that occurs upon blood flow restoration after ischemia. LIRI can lead to severe complications, including primary graft dysfunction in lung transplants and multi-organ failure. However, current treatments remain limited.
View Article and Find Full Text PDFContemp Clin Trials
September 2025
Weill Cornell Medicine Center for Global Health, New York, NY, USA.
Introduction: Preclinical and clinical study data show that combining bedaquiline (B or BDQ), moxifloxacin (M), and pyrazinamide (Z), known as BMZ, has potent antimicrobial activity that might shorten treatment duration for drug-susceptible pulmonary tuberculosis.
Methods/design: We describe the design of Tuberculosis Trials Consortium (TBTC) Study 38/CRUSH-TB (NCT05766267), an open-label multicenter international randomized controlled phase 2C trial that compares two four-month regimens, BMZ plus rifabutin (Rb) (2BMZRb/2BMRb) or BMZ plus delamanid (D or DLM) (2BMZD/2BMD), with standard 6-months isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). All drugs are administered seven days per week, under direct observation, at least five days per week.